Results 121 to 130 of about 16,017 (247)
Advances in the molecular regulation mechanism of tumor dormancy and its therapeutic strategy
Tumor dormancy is a stage in the growth and development of malignant cells and is one of the biological characteristics of malignant cells. Complex transitions involving dormant tumor cells between quiescent and proliferative states pose challenges for ...
Yuan Wang +7 more
doaj +1 more source
A Systemic Model for Understanding Business Interactions With Biodiversity and Ecosystems
ABSTRACT Biodiversity loss and ecosystem degradation represent critical threats to human well‐being and economic resilience, challenging businesses to understand and manage their interdependence with natural systems. This study develops a systemic framework—the BioModel—that elucidates the reciprocal relationship between businesses, biodiversity, and ...
Lino Cinquini +2 more
wiley +1 more source
Demonstration of nanofiltration‐based virus safety for AAV manufacturing using model viruses
Abstract Virus safety for biopharmaceutical products has been a well‐established concern for several decades. While various virus reduction steps have been identified and implemented for traditional plasma‐derived and monoclonal antibody products, there are various challenges to achieving the same virus safety in emerging gene therapy products.
Brian Buesing +2 more
wiley +1 more source
Editorial: From microbial immunology to microbial therapeutics via targeted delivery technology
Matteo Puccetti +3 more
doaj +1 more source
DNA concentration in harvest affects retrovirus clearance capabilities of protein A chromatography
Abstract Protein A chromatography is a key unit operation in biopharmaceutical purification, widely used to capture monoclonal antibodies (mAbs) from harvest cell culture fluid (HCCF). In addition to its primary function, protein A chromatography is also frequently tested for its ability to remove viruses. Although protein A specifically binds mAbs and
Lukas Döring +7 more
wiley +1 more source
Regenerative perfusion bioreactor for biologics production with lower COGs
Abstract Perfusion bioreactor systems enable intensified bioprocessing with high cell densities and volumetric productivities in monoclonal antibody (mAb) manufacturing. However, their widespread adoption remains constrained by the high consumption of chemically defined cell culture media.
Eric Wynne +5 more
wiley +1 more source
Abstract Recombinant adeno‐associated virus production for gene therapy applications commonly relies on the Spodoptera frugiperda 9 (Sf9) baculovirus infection platform. The process encompasses cell expansion from flasks through intermediate‐scale bioreactors to large‐scale production.
Min Tae Park, Seyed Pouria Motevalian
wiley +1 more source
Abstract Increasing protein therapeutics production by adopting intensified perfusion cultures places high demand on the mass transfer capabilities of single‐use bioreactors (SUB). Here, we compare these capabilities for four SUB designs against worst‐case O2 transfer requirements for supporting Chinese hamster ovary (CHO) perfusion cultures. Impact of
Anita B. Dabek +9 more
wiley +1 more source
Correction: Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]
Hamida JA +7 more
europepmc +2 more sources
Flocculation using cationic polymers leads to the creation of large floc complexes. Negative charged species like cells, cell debris, and negatively charged host cell impurities like host cell DNA and host cell proteins are trapped within the complex while the positively charged monoclonal antibody stays in solution.
Anna‐Carina Frank +9 more
wiley +1 more source

